开源证券给予赛诺医疗买入评级：2025H1业绩符合预期，神介业务步入收获期

Group 1 - The core viewpoint of the report is that Open Source Securities has given a "buy" rating for Sino Medical (688108.SH) based on its recent developments and market potential [1] - The intracranial self-expanding drug-eluting stent has entered the FDA's green channel, indicating that the neurointerventional business is entering a harvest period [1] - The coronary business is progressing smoothly with domestic centralized procurement, and there is potential for accelerated expansion in overseas markets [1]